- Who are you and what do you do? DBV Technologies is a global biopharmaceutical company that’s developing investigational epicutaneous immunotherapy (EPITTM) technology to treat millions of people suffering from life-threatening food allergies and other immunological disorders. Starting with peanut, we are investigating food allergy treatments that are designed to potentially reduce the risk of unpredictable, life-threatening reactions due to accidental exposure.
- What are your business objectives with regards to allergy and supporting people with allergic disease? DBV Technologies was founded by paediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. Currently, there remains a significant unmet medical need in food allergy treatment. Strict avoidance of offending allergens and management of allergic reactions is common practice in helping to prevent serious health consequences for these patients. At DBV, we are committed to investigating and developing potential treatments for food allergies.
- Why have you chosen to partner with Allergy UK? Allergy UK is a leading organisation that provides support, advice, and information for those living with allergic disease. We are proud to partner with such a reputable charity that provides much needed support and educational materials for food allergic families.
- What is the overall objective for the partnership? DBV believes that patients are at the core of everything that we do. We have a dedicated team of people across our organisation, from our experienced leaders to our science-driven colleagues, that are committed to discovering safe and effective treatments for patients with food allergies and other unmet medical needs. We work closely with patient advocates, professional organisations, and other stakeholders to understand the needs of patients, families, caregivers, and others impacted by food allergies. We support Allergy UK in advancing important initiatives to serve the community and value this trusted partnership.